Enliven Therapeutics, Inc. (ELVN)
(Delayed Data from NSDQ)
$20.94 USD
+0.74 (3.66%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $20.91 -0.03 (-0.14%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ELVN 20.94 +0.74(3.66%)
Will ELVN be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for ELVN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ELVN
3 Stocks in the Limelight on New Analyst Coverage
ELVN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for ELVN
Enliven Therapeutics’ ELVN-001 Poised for Success in CML Market Following Scemblix Data: A Buy Rating
Enliven Therapeutics to Present at Two Upcoming Investor Conferences
Strong Buy Rating for Enliven Therapeutics’ ELVN-001 Amid Favorable Market Dynamics
Short Report: GameStop, AMC Entertainment bears retreat further
Enliven Therapeutics: A Strong Buy on Market Dynamics and Scemblix’s Breakthrough Therapy Designation Impact